---
title: "乐普生物-B：MRG003 的注册性临床研究结果以 LBA 形式于 2025 年 ASCO 年会上公布"
description: "乐普生物-B 宣布，其候选药物 MRG003 的关键注册性临床研究结果将于 2025 年 ASCO 年会上以重磅研究摘要形式公布，并进行口头报告。MRG003 是一种针对复发性或转移性鼻咽癌的创新型抗体药物偶联物。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/242710983.md"
published_at: "2025-06-01T10:50:07.000Z"
---

# 乐普生物-B：MRG003 的注册性临床研究结果以 LBA 形式于 2025 年 ASCO 年会上公布

> 乐普生物-B 宣布，其候选药物 MRG003 的关键注册性临床研究结果将于 2025 年 ASCO 年会上以重磅研究摘要形式公布，并进行口头报告。MRG003 是一种针对复发性或转移性鼻咽癌的创新型抗体药物偶联物。

智通财经 APP 讯，乐普生物-B(02157) 发布公告，公司自主研发的候选药物 MRG003(一种表皮生长因子受体靶向创新型抗体药物偶联物 (“ADC”) 候选药物，用于治疗复发性或转移性鼻咽癌 (“R/M NPC”)) 的关键注册性临床研究结果，于 2025 年美国临床肿瘤学会 (“ASCO”) 年会上以 “重磅研究摘要 (LBA)” 形式公布，并于会上作口头报告。

### Related Stocks

- [02157.HK - 乐普生物-B](https://longbridge.com/zh-CN/quote/02157.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shootin' the Bull about wave 5 of 5 of B | Shootin' the Bull about wave 5 of 5 of B | [Link](https://longbridge.com/zh-CN/news/276266924.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/zh-CN/news/276199846.md) |
| MBV International Says Unit To Sell 20,000 Ordinary Shares In Lordan Group At HK$31.4 Mln | MBV International Ltd :UNIT TO SELL 20,000 ORDINARY SHARES IN LORDAN GROUP AT HK$31.4 MILLION | [Link](https://longbridge.com/zh-CN/news/276043299.md) |
| This backup camera cleaner hides behind your license plate | A Vermont startup has launched the Lens Lizard, a backup camera cleaner that installs using existing license plate screw | [Link](https://longbridge.com/zh-CN/news/276150329.md) |
| Deep-sea fish break the mold with novel visual system | New research has identified a novel type of visual cell in deep-sea fish, blending features of rods and cones, adapted f | [Link](https://longbridge.com/zh-CN/news/276218702.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。